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Necroptosis is a regulated form of cell death involved in several disease
models including in particular liver diseases. Receptor-interacting protein
kinases, RIPK1 and RIPK3, are the main serine/threonine kinases driving
this cell death pathway. We screened a noncommercial, kinase-focused
chemical library which allowed us to identify Sibiriline as a new inhibitor
of necroptosis induced by tumor necrosis factor (TNF) in Fas-associated
protein with death domain (FADD)-deficient Jurkat cells. Moreover, Sib
inhibits necroptotic cell death induced by various death ligands in human
or mouse cells while not protecting from caspase-dependent apoptosis. By
using competition binding assay and recombinant kinase assays, we
demonstrated that Sib is a rather specific competitive RIPK1 inhibitor.
Molecular docking analysis shows that Sib is trapped closed to human
RIPK1 adenosine triphosphate-binding site in a relatively hydrophobic
pocket locking RIPK1 in an inactive conformation. In agreement with its
RIPK1 inhibitory property, Sib inhibits both TNF-induced RIPK1-
dependent necroptosis and RIPK1-dependent apoptosis. Finally, Sib
protects mice from concanavalin A-induced hepatitis. These results reveal
the small-molecule Sib as a new RIPK1 inhibitor potentially of interest for
the treatment of immune-dependent hepatitis.
Abbreviations
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ATP, adenosine triphosphate; AU, arbitrary unit; DR, death receptor; FasL,
Fas ligand; MD, molecular docking; MEFs, mouse embryonic fibroblasts; Nec-1, necrostatin-1; RT, room temperature; Sib-i, inactive
Sibiriline; Sib, Sibiriline; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand.
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Introduction
Excessive hepatocyte cell death has been identified as a
central pathophysiological mechanism in both acute
and chronic liver injuries, involving mostly cell death
by apoptosis and necrosis (oncosis) [1]. More recently,
necroptosis, a specific form of regulated necrosis, has
also been implicated in liver disease models [2,3].
Necroptosis is a caspase-independent nonapoptotic
backup cell death mechanism initiated upon blockade
of apoptosis [4]. This cell death pathway is dependent
on serine/threonine receptor-interacting protein
kinases, RIPK1 and RIPK3, and a pseudokinase
MLKL (mixed-lineage kinase domain-like) (see for
review [5]). Moreover, it is inhibited by necrostatin-1
(Nec-1), the first small tryptophan-based molecule
inhibitor of RIPK1 kinase activity [4,6].
Necroptosis may occur in response to various stim-
uli [5]. The tumor necrosis factor (TNF)-induced
necroptosis pathway has been most intensively studied.
Upon TNF stimulation when caspase-8 is inhibited or
absent [7,8], RIPK1 in complex II recruits RIPK3,
resulting in autophosphorylation and activation of the
latter. Caspase-8 and FLIPL in complex II negatively
regulates RIPK1 and RIPK3 by proteolysis [9]. Then,
these kinases interact with each other via their RIP
homotypic interaction motif (RHIM) domains promot-
ing necrosome formation [10], recruitment and phos-
phorylation of MLKL [11,12] which in turn
oligomerizes [13] and is recruited to negatively charged
phosphoinositolphosphates [14], causing loss of plasma
membrane integrity [15]. Necroptosis contributes to
the pathogenesis of several inflammatory diseases
including ischemic reperfusion injury, acute pancreati-
tis, sepsis, neurodegeneration, and viral infection [16].
Although the contribution of necroptosis in liver dis-
ease is still an open question [17], some studies
reported that necroptosis is also involved in inflamma-
tory-driven liver diseases. On one hand, RIPK3-
deficient mice are protected from ethanol- and
acetaminophen (APAP)-induced hepatocyte injury or
nonalcoholic steatohepatitis (NASH) [18–20]. On the
other hand, RIPK3 expression is increased in liver
biopsies of chronic ethanol-fed mice, alcoholic liver
disease patients, NASH patients, or patients with other
chronic liver diseases (hepatitis B and C) [18,20,21].
Furthermore, Nec-1 or Nec-1s protects against APAP-
or concanavalin A-induced hepatoxicity [22–25]. To
date, the only possible candidate to be used in the
clinic would be the anticancer drug B-RafV600E Dab-
rafenib which besides mutant Raf targeting also inhi-
bits RIPK3 and alleviates APAP-induced liver injury
[26]. Altogether these data suggest that targeting
necroptosis could be a novel therapeutic strategy for
liver diseases.
Nec-1 (5-((1H-indol-3-yl)methyl)-3-methyl-2-thioxoi-
midazolidin-4-one) was identified in a phenotype
screen for small molecule inhibiting TNF-induced
necroptosis in human monocytic U937 cells [4,27], and
further was shown to be an allosteric inhibitor of
RIPK1 kinase [6]. However, Nec-1 is not specific for
RIPK1 because its chemical scaffold is similar to
methyl-thiohydantoin-trytophan, an inhibitor of indo-
leamine 2,3-dioxygenase (IDO), an immune regulator
[28]. Structure–activity relationship (SAR) study
revealed that small substituent Cl at the position 7 of
the indole ring leads to the compound necrostatin-1s
(Nec-1s) [27] having an increased selective RIPK1 inhi-
bitory activity [29] and lacking IDO inhibitory activity
[28]. However, necrostatins have poor pharmacokinetic
properties. More recently, other classes of compounds
were described such as the 1-aminoisoquinolines,
5-phenylpyrrolo[2,3-b]pyridines, 5-arylpyrrolo[2,3-b]
pyridines, furo[2,3-d]pyrimidines, analogs of Bcr-Abl
inhibitor ponatinib, PN10 (fusion of the scaffold of
ponatinib and Nec-1s), the benzo[b]1,4]oxazepin-4-
ones, the compound GSK’963, and the N-benzyl-
N-hydroxy-2,2-dimethylbutanamide [30–36]. The
previously described biological activities validate
kinase RIPK1 as a promising therapeutic target for
discovering new compounds to treat various human
disorders [37]. The quest for an optimized clinical can-
didate is still in progress with the synthesis of the first-
in-class RIP1 kinase-specific inhibitor (GSK2982772)
[38] and will benefit from the description of new
potent RIPK1 inhibitors.
In order to find new inhibitors of RIPK1, we
screened an in-house kinase-focused library of small
chemical compounds (the ReCC, Roscoff essential
Chemical Collection, Roscoff, France) using a pheno-
typic screen based on the inhibition of TNF-induced
necroptosis in human FADD-deficient Jurkat T cells
(in vitro model described in Ref. [39]). Among 1015
tested compounds, 4-(1H-pyrrolo[2,3-b]pyridin-2-yl)
phenol [Sibiriline (Sib)] was selected as the best hit.
Interestingly, we describe here the biochemical proper-
ties and both in vitro and in vivo effects of this new
pyrrolo[2,3-b]pyridine-based derivative as a potent
RIPK1 inhibitor/necroptosis inhibitor. Our results
indicate that the kinase activity of RIPK1 is dose-
dependently affected by Sib. In silico molecular model-
ing and docking studies reveal that Sib interacts with
RIPK1 kinase domain in a hydrophobic ‘back’ pocket
[32], between the gatekeeper and the DFG (DLG in
RIPK1) motif, adjacent to the adenosine triphosphate
(ATP)-binding site, thus locking RIPK1 in an inactive
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DLG out conformation. Finally, to assess the thera-
peutic efficacy of Sib in liver diseases, we studied its
effects in concanavalin A-induced hepatitis in C57Bl/6
mice. This acute hepatitis is a mouse model of
immune-mediated liver injury [40]. A single intraperi-
toneal injection of Sib protects mice from liver injury
induced by concanavalin A, and therefore, reveals Sib
as a promising new chemical scaffold of RIPK1 inhibi-
tor, with a straightforward, high-yielding synthesis,
which is effective in the treatment of the preclinical
model of immune-dependent hepatitis.
Results
Sibiriline is a new necroptosis inhibitor
To identify novel necroptosis inhibitors, we screened a
noncommercial, kinase-focused chemical library of
1015 compounds for their ability to block TNF-
induced necroptosis in FADD-deficient human Jurkat
cells (Fig. 1A). These compounds were tested at the
concentration of 10 lM and compared to the well-
characterized RIPK1 inhibitor necrostatin-1 (Nec-1).
Among the tested drugs, Sib stood out as the most
potent molecule at rescuing cells from necroptotic cell
death, whereas Sib-i came out as its inactive analog
(Fig. 1B). Similar to Nec-1 (EC50 = 0.3 lM), Sib effi-
ciently blocked necroptotic death in FADD-deficient
Jurkat cells in a concentration-dependent manner with
an EC50 value of 1.2 lM (Fig. 1C). The inactive
derivative Sib-i was unable to block necroptosis in
FADD-deficient Jurkat cells even at the high concen-
tration of 50 lM (Fig. 1C). Importantly, Sib has a very
low cytotoxic effect against human peripheral blood
leukocytes (PBL) (Fig. 2A) or human retinal pigment
epithelial cells (RPE-1 hTERT) (Fig. 2B).
Sib blocks necroptotic but not apoptotic cell
death
To further analyze Sib inhibitory effect, we compared
the ability of Sib and Nec-1 to block necroptosis in
murine and human cell lines in vitro. Necroptosis was
induced by a wide range of well-described necroptotic
stimuli such as TRAIL + zVAD-fmk, TNF + zVAD-
fmk, or FasL + zVAD-fmk in human U937 or mouse
L929 sAhFas cells. In all of these models, Sib effi-
ciently blocked necroptosis in a dose-dependent man-
ner, and with an efficacy almost similar to Nec-1
(Fig. 3A). This efficient protection from necroptosis by
Sib was evidenced by measurements of both plasma
membrane permeabilization (% of propidium iodide
(PI)-positive cells) and intracellular ATP levels
(Fig. 3A). This latter assay highlighted the fact that
Sib inhibitory effect appeared at 2.5 lM and was
almost complete at 5 lM. Notably and like Nec-1, Sib
did not rescue from apoptosis induced by TRAIL,
FasL, or staurosporine in Jurkat cells (Fig. 3B,C),
showing that Sib is a selective inhibitor of necroptosis
but not of apoptosis. It is to be noted that in a differ-
ent human cell line resistant to extrinsic apoptosis, the
FADD-deficient Jurkat cells, TNF-induced necroptosis
can also be prevented by Sib. Conversely, Fas-induced
apoptosis in the L929 sAhFas mouse model is not sen-
sitive to Sib (data not shown). Overall, these data
evidenced that Sib specificity toward inhibiting necrop-
tosis, but not apoptosis, does not depend upon the
stimuli, the cell type, or even the species.
Sib rescues cells from necroptosis even after cell
death initiation and allows cell survival and
proliferation
In the hypothetical perspective of using Sib as a
necroptosis inhibitor in medicine, we tested its activity
when administered after, rather than before, necropto-
sis initiation. In the following experimental setup, Sib
or Nec-1 was added at the nontoxic concentration of
10 lM between 1 to 4 h after TNF-dependent necrop-
tosis induction in FADD-deficient Jurkat cells. When
added in the first couple of hours following necropto-
sis induction, Sib promotes an almost complete recov-
ery by decreasing cell death to approximately 10%.
When added 3 or 4 h after necroptosis induction, both
Sib or Nec-1 treatment rescued necroptotic FADD-
deficient Jurkat cells, reducing by a minimum of 50%
the number of PI-positive cells (Fig. 4A). To further
refine Sib’s potential at preventing cells from a necrop-
totic wave, a clonogenic assay was performed 24 h
after necroptosis induction by TNF + zVAD-fmk in
L929 cells in the presence or absence of Sib, Sib-i,
Nec-1, or Nec-1s. Eight days later, culture plates were
stained with crystal violet and showed that treatment
with Sib, Nec-1, or Nec-1s but not with Sib-i allowed
the formation of colonies (Fig. 4B), suggesting that
Sib as other well-known necroptosis inhibitors (Nec-1
or Nec-1s), not only protected cells from cell death but
also allowed them to survive and proliferate.
Sib is a potent inhibitor of RIPK1
In order to investigate the mechanism of action of Sib
and its target, the selectivity of Sib and Sib-i was
tested at 10 lM against a panel of 456 kinases includ-
ing eight lipid kinases in an in vitro competition bind-
ing assay (KINOMEscan; DiscoverX, San Diego, CA,
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USA). RIPK1 was shown to be among the top kinases
targeted by Sib as only 0.2% of the initial amount of
the kinase was still on the affinity matrix after compe-
tition with Sib (Table S1 and blue circle on Fig. 5A).
Sib-i is not a potent interactor of the tested kinases
(Fig. 5A). Death-associated protein kinase-3 (DAPK3)
is only poorly affected by Sib-i (32% of the initial
amount of kinase is still on the affinity matrix after
competition with 10 lM Sib-i, Fig. 5A). Using this
competition binding assay, the dissociation constant
(Kd) of Sib for RIPK1 was calculated with a standard
dose–response curve and showed the high affinity of
Sib for RIPK1 with a Kd in nM range and equal to
218 nM (Fig. 5B, left panel). High affinity of Nec-1 or
Nec-1s for RIPK1 was also confirmed with Kd equal
to 31 nM or 8 nM, respectively (Fig. 5B, right panel).
To further confirm the inhibition of RIPK1 enzy-
matic activity by Sib, an in vitro autophosphorylation
assay using recombinant full-length RIPK1 (GST-
tagged) was performed. This assay showed an
inhibition of RIPK1 autophosphorylation by Sib in a
dose-dependent manner, Sib-i having no effect
(Fig. 6A). The catalytic activity of RIPK1 was also
quantified by monitoring the phosphorylation of mye-
lin basic protein (MBP), a known substrate of RIPK1.
Consistently, Sib efficiently inhibits the phosphoryla-
tion of MBP in a dose-dependent manner with an IC50
equal to 1.03 lM (Fig. 6B).
Finally, to characterize the mechanism of RIPK1
inhibition by Sib, we analyzed the effect of increasing
the concentrations of ATP (up to 1 mM of cold ATP)
on the inhibition of autophosphorylation by 10 lM of
Sib. Results obtained show that in the presence of
1 mM cold ATP, the inhibition of the RIPK1
autophosphorylation by Sib was decreased. It suggests
an ATP-competitive mechanism of RIPK1 inhibition
by Sib (Fig. 6C). This result was previously described
for Nec-1 [6]. Very interestingly, Sib had a very low
inhibitory effect on RIPK3 kinase activity with an
IC50 equal to 101.9 lM (Fig. 6D). Altogether, these
data demonstrated that Sib is a specific inhibitor of
RIPK1 kinase activity. In agreement with this bio-
chemical activity, Sib was able, with a similar efficacy
to Nec-1, to inhibit RIPK1-dependent necroptosis
induced by the combination TNF + TAK1i + zVAD-
fmk by reducing the percentage of Syber Green (%
SG)-positive cells measured in function of time
(Fig. 7A, left panel). This necroptotic pathway was
characterized by the lack of caspase-3 activity (very
low DEVD-AMC fluorescence) (Fig. 7A, right panel).
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Fig. 2. At inhibitory concentration, Sibiriline is not toxic toward
human primary leukocytes or retina cells. Twenty-four hour after
Sibiriline treatment, cell viability was measured with an MTS assay
to determine the toxicity of the compound toward either (A) human
primary blood leukocytes (hPBLs, n = 6 individuals, mean  SD) or
(B) human retina pigmented epithelium cells (RPE-1 hTERT, n = 3,
mean  SD).
Fig. 1. Identification of Sibiriline as potent necroptosis inhibitor by cell-based screening of chemical library. (A) Workflow of the cell-based
selection of new necroptosis inhibitors. Among 1015 compounds, 4-(1H-pyrrolo[2,3-b]pyridin-2-yl)phenol (Sibiriline, Sib) was selected as an
inhibitor of TNFa-induced necroptosis in human FADD-deficient Jurkat cells. The different steps of the selection are reported in the inverted
triangle. Inactive Sibiriline (Sib-i) was not detected during the screening campaign and is thus considered as the negative control of Sibiriline.
(B) Results of the automated cell-based screening assay highlighting putative necroptosis inhibitor candidates shown in scatter plot. Ninety-
six compounds were screened per plate (including eight positive and eight negative controls) for their antinecroptotic activity on Jurkat
FADD-deficient cell line treated with TNF-a. Cell viability was evaluated by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) reduction assay, 24 h after addition of tested compounds on cells and is expressed in % of survival in
cells treated with DMSO. The primary screening is performed in monoplicate. (C) Dose-dependent inhibition of TNF-a-induced necroptosis
by increasing concentrations of Sibiriline. After a 24-h incubation, the effect of the tested compound on the cell viability was evaluated by
MTS reduction assay and is expressed in % of survival in cells treated with DMSO (n = 3, mean  SD).
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Moreover, Sib like Nec-1 inhibited RIPK1-dependent
apoptosis induced by the combination of
TNF + TAK1i [41,42] by decreasing both the % SG-
positive cells and caspase-3 activity measured as a
function of time (Fig. 7B).
Molecular modeling of the RIPK1–Sib complex
To further understand the mechanism of inhibition by
the small chemical compound, we studied in silico the
RIPK1–Sib complex to establish a possible model of
RIPK1 inhibition by Sib. Molecular docking simula-
tions of Sib to RIPK1 kinase and molecular dynamics
trajectory computed for the best complex indicated a
preferential binding mode similar to the one described
for Nec-1s on a site next to the ATP-binding site
(Figs 8 and 9). Contact residues determined included
notably the seven key amino acids (Leu70, Val76,
Leu78, Leu90, Asp156, Ser161, and Phe162) (Fig. 8A)
involved in the interaction with necrostatins (see [43]
for details on RIPK1–Necrostatins complexes). An
exhaustive list of surrounding residues (3.5 A cut-off)
also included the amino acids Met67, Lys77, Lys79,
Met92, Val134, and Ile154 (Fig. 9). Note here that
Met92 is the gatekeeper residue of RIPK1 [6] and the
catalytic triad residues are Lys45, Glu63, and Asp156
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Fig. 3. Sibiriline inhibits death receptor-induced necroptosis but not apoptosis. (A) Necroptosis was induced in U937 cells by a pretreatment
with zVAD-fmk (20 lM) followed by a 24-h treatment with TRAIL-Flag (10 ngmL1). In L929 sAhFas cell line, the same zVAD-fmk
pretreatment was followed either with a TNF (10 ngmL1) or an Ig-FasL (200 ngmL1) 16-h treatment. The percentage of cell death was
determined by propidium iodide staining using flow cytometry (upper panels) (n = 3, mean  SEM, *P < 0.05, **P < 0.01, ***P < 0.001
and ****P < 0.0001). Intracellular ATP levels (lower panels) were measured with the CellTiter-Glo Luminescent Cell Viability Assay (n = 3,
mean  SEM, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001). Apoptosis was induced in Jurkat wild-type cells with either (B) a
TRAIL-Flag (10 ngmL1) or Ig-FasL (200 ngmL1) or (C) staurosporine (100 nM) 18-h treatment. The percentage of cell death was quantified
by flow cytometry using propidium iodide staining (n = 3, mean  SD). Results shown are representative of at least three independent
experiments.
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as reported [43]. Sib thus binds in the ‘back’ pocket of
RIPK1 between the DLG motif and the gatekeeper.
Despite the presence of a canonical H-bond donor/
H-bond acceptor motif, Sib, like Nec-1s, does not
appear to bind to the hinge region, at least in this con-
formation of the protein (Fig. 8B,C).
In contrast, the inactive compound Sib-i did not
contact the C-lobe region of RIPK1 (Fig. 9). Compar-
ison between the contact residues predicted for active
compounds (Sib and Nec-1s) and inactive compound
(Sib-i) did indicate the position of a good inhibitor
that should promote hydrophobic interactions with the
long helix defined by residues from Pro111 to Lys132,
thus locking the conformation of the enzyme by reduc-
ing the mobility of the two main subdomains of the
kinase toward each other (Fig. 9).
Sib protects mice from concanavalin A-induced
hepatitis
The identification of Sib as a specific necroptosis and
RIPK1 inhibitor as Nec-1 prompted us to test this
compound in a murine model of immune-dependent
hepatitis induced by concanavalin A treatment. In this
model, we have previously demonstrated a protective
effect of an intravenous injection of Nec-1 or Nec-1s
against concanavalin A-induced hepatitis [22,25]. Here,
we studied the protective effect of an intraperitoneal
injection of 3 mgkg1 Sib or 6.25 mgkg1 Nec-1s 1 h
before an intravenous injection of 12 mgkg1 con-
canavalin A.
Pretreatment with either Sib or Nec-1s protected
mice from concanavalin A-induced hepatotoxicity by
significantly decreasing serum aspartate aminotrans-
ferase (AST)/alanine aminotransferase (ALT) levels
measured 24 h after treatment (Fig. 10A). Moreover,
Sib or Nec-1s significantly decreased liver damage by
reducing the size of perivascular and parenchymal
zones of necrosis stained with hematoxylin and eosin
(Fig. 10B, see arrows) and the percentage of necrotic
area (Fig. 10C). In accord with the protection afforded
by Sib or Nec-1s, the loss of mouse body weight
induced by concanavalin A treatment was significantly
reduced by Sib or Nec-1s pretreatment (Fig. 11). Alto-
gether these data suggest that 3 mgkg1 Sib had an
almost comparable efficacy to 6.25 mgkg1 Nec-1s in
protecting mice against concanavalin A-induced
hepatitis.
Discussion
By using a cellular screen and a unique noncommer-
cial, kinase-focused chemical library of 1015 small
molecular compounds, we identified a new inhibitor of
TNF-induced necroptosis in Jurkat FADD-deficient
cells with a micromolar EC50 concentration. Sib,
4-(1H-pyrrolo[2,3-b]pyridin-2-yl)phenol is a new pyr-
rolo[2,3-b]pyridine-based derivative compound. Our
present data enlarge the number of small chemical
compounds having a potent necroptosis inhibitory
activity [44]. Sib was also able to inhibit TRAIL- or
FasL-induced necroptosis but not apoptosis regardless
of the human or murine cell line origin. Protection
from necroptotic cell death was obtained at 1–5 lM
concentration of Sib in our diverse cellular systems,
suggesting a large therapeutic window for potential
clinical application. Moreover, protection from
necroptosis has been afforded by Sib up to 4 h after
the induction of death, which could allow a therapeu-
tic potential in the case of cardiac infarction or stroke.
Regarding the mode of action underlying necroptosis
inhibition by Sib, a KINOMEscan competition bind-
ing assay at DiscoverX (456 kinases and activated
mutant kinases) was performed and showed that
RIPK1 was the top kinase inhibited by Sib. In
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Fig. 4. Sibiriline remains effective at preventing necroptosis when
applied post cell death initiation and allows cell survival and
proliferation. (A) Viability was assessed by flow cytometry with
propidium iodide (PI) staining on FADD-deficient Jurkat cells
treated with TNF (10 ngmL1) followed by 10 lM Sibiriline (Sib) or
necrostatin-1 (Nec-1) addition 1–4 h post necroptosis initiation
(n = 4, mean  SEM, ***P < 0.001 and ****P < 0.0001). (B)
Clonogenic assay was performed in L929 cells. Twenty-four hour
after TNF+zVAD-fmk treatment in the absence or presence of
10 lM necroptosis inhibitors (Nec-1, Nec-1s, or Sib) or 10 lM Sib-i,
1000 cells per well were plated and stained with crystal violet
8 days later. One representative of three experiments is shown.
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contrast to Nec-1 which did not bind to RIPK2 and
RIPK4 [45], Sib bound to RIPK4 to a certain extent
(Table S1). We showed in this study that the kinase
activity of RIPK3 is only poorly affected by Sib (ap-
proximately 100 times less potently inhibited compared
to RIPK1). The KINOMEscan also revealed that
JAK2, PDGFRb, KIT, and KIT (V559D) are other
major kinases targeted by Sib. Chemical synthesis of
Sib analogs, notably driven by the molecular docking
reported in this study, would be necessary to improve
the selectivity of this compound. As expected, no
kinase was efficiently targeted by the inactive counter-
part, Sib-i. We also determined a Kd binding constant
of Sib for RIPK1 of 218 nM, whereas the Kd of Sib-i
was greater than 30 000 nM. The in vitro competitive
assay used for both Kd study and kinase profiling is
based on an active site/ligand binding technology
developed by DiscoverX (Fremont, CA, USA): it can
detect the effect of compounds that bind the kinase
active site and directly (sterically) or indirectly (al-
losterically) prevent kinase binding to one immobilized
ligand. The majority of kinase inhibitors developed to
date target the ATP-binding site. Based on the selectiv-
ity reported for Sib, we hypothesized that Sib also tar-
gets the ATP-binding site of RIPK1. We showed here
that ATP competes with Sib for the inhibition of
RIPK1 autophosphorylation (Fig. 6C). Such result
was already described for Nec-1 [6], suggesting some
similarities in the mode of action between Sib and
Nec-1. In silico molecular modeling and docking stud-
ies highlighted these similarities. To understand the
interaction mode of Sib with RIPK1, molecular dock-
ing was performed based on the cocrystal structure of
RIPK1 with Nec-1s (PDB: code 4ITH). The predictive
binding mode was shown on Fig. 8. As was the case
for Nec-1s, Sib was located in the hydrophobic ‘back’
[32] pocket between the N-lobe and C-lobe of the
RIPK1 kinase domain, interacting with both the DLG
motif and the gatekeeper. This pocket is formed by a
number of residues including Leu70, Val76, Leu78,
Leu90, Asp156, Ser161, and Phe162 (see [43] for
details on RIPK1-Necrostatins complexes). In analogy
with the inhibition of RIPK1 by Nec-1s, we hypothe-
sized that Sib locks RIPK1 in an inactive conforma-
tion (‘DLG (Asp-Leu-Gly)-out’ state of kinase)
notably by interaction with Asp156 of the DLG motif
and neighboring Ser161. Interactions with the C-lobe
also appear to be an important element for successful
inhibition. Our results suggest that Sib shares charac-
teristics of the type II kinase inhibitor class, which tar-
get the inactive enzymatic conformation, with the
caveat that it does not interact with the hinge region,
despite its H-bond donor–H-bond acceptor motif. As
the description of the druggability of necroptosis [4],
numerous chemobiological studies have led to the dis-
covery of molecules that can bind to the catalytic site
of RIPK1 [37]. As examples, compounds characterized
by a GlaxoSmithKline group include notably pyrrolo
[2,3 b]pyridine-based derivatives [30]. Interestingly, and
similar to the putative mechanism of Sib described
here, these small chemical compounds also share all
characteristics of the type II kinase inhibitor class.
This class of compounds is believed to perturb the Phe
side chains of the catalytic site inwards to obstruct the
ATP-binding cleft.
As Nec-1 or Nec-1s has already been shown to pro-
tect mice from concanavalin A-induced hepatitis
[22,24,25], we tested the effect of Sib in this model of
murine hepatitis. Pretreatment of mice with 3 mgkg1
Sib has almost the same protective effect against con-
canavalin A-induced hepatitis than pretreatment of
mice with 6.25 mgkg1 Nec-1s, by decreasing serum
Fig. 5. Study of the binding of Sibiriline to RIPK1 and to a large panel of kinases. (A) Biochemical kinase profiling assay (KINOMEscanSM)
which measures drug binding with a panel of 456 purified kinases (mostly human). This TREEspotTM Kinase dendrogram (DiscoverX) is an
artistic representation of the human kinome phylogenetic tree. The codes reported on this figure indicate the subclasses of protein kinases:
CMGC for CDKs, MAP kinases, GSK and CDK-like kinases; AGC for protein kinase A, G, and C families (PKA, PKC, PKG); CAMK for Ca2+/
calmodulin-dependent protein kinases; CK1, cell kinases 1 (originally known as casein kinase 1); STE, STE kinases (homologs of yeast
STErile kinases); TKL, tyrosine kinases-like; TK, tyrosine kinases. Each kinase tested in the assay panel is marked with a circle. The hit
kinases reported are marked with a red circle, except RIPK1 which is marked with a blue circle. 0% represents the higher affinity, whereas
small green dots indicate that at the tested concentration of molecule (here 10 lM), Sib or Sib-i cannot bind significantly to the kinase (as
over 35% of the tested kinase are still on the affinity matrix after competition with the tested compound). For RIPK1, only 0.2% of the
initial amount of kinase is still on the affinity matrix after competition with 10 lM Sibiriline (the full list of results for Sibiriline is reported in
Table S1). Selectivity Score (reported on the figure as S-Score) is a value related to compound selectivity. It is calculated by dividing the
number of kinases that compounds bind to by the total number of distinct kinases tested, excluding mutant variants. S-Score(35) = (number
of nonmutant kinases with %Ctrl < 35)/(number of nonmutant kinases tested). Images were generated using TREEspotTM Software Tool and
reprinted with permission from KINOMEscan, a division of DiscoverX Corporation. (B) Measure of the binding constant for RIPK1/Sibiriline
interaction. An 11-point threefold serial dilution of Sib, Sib-i, Nec-1, or Nec-1s were prepared in 100% DMSO in order to determine the
binding constant (Kd). Kds are calculated by measuring the amount of kinase captured on the solid support as a function of the test
compound concentration (n = 2, mean  SEM).
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AST/ALT levels and liver injury. Sib seems to have no
toxic adverse effect as this compound allowed mice to
recover some weight after concanavalin A treatment.
Altogether these data demonstrated efficacy of Sib
in vivo which make Sib to be a highly promising tem-
plate for lead optimization.
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Materials and methods
Cell lines and culture conditions
SV40 large T-immortalized mouse embryonic fibroblasts
(MEFs) and L929 sAhFas were kind gifts of the University
of Ghent (Belgium). These cell lines were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) high glu-
cose (Invitrogen/Thermo Fisher Scientific, Villebon sur
Yvette, France) supplemented with 10% FCS and 2 mM L-
glutamine (Invitrogen/Thermo Fisher Scientific). HT29,
Jurkat wild-type A3, FADD-deficient Jurkat I 2.1, L929,
U937, RPE-1 hTERT human cell lines were obtained from
ATCC (American Type Culture Collection, Rockville, MD,
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Fig. 7. Sibiriline prevents RIPK1-dependent cell death upon TNF stimulation. The percentage of cell death (SytoxGreen fluorescence intensity)
and caspase-3 activity expressed in arbitrary units (DEVD-AMC fluorescence intensity) were measured in function of the time by using a
Fluostar Omega fluorescence plate reader as described in Materials and methods. MEF cells were pretreated or not (DMSO) with the indicated
compounds (Nec-1, Sib, Sib-i) at 10 lM and TAK1i at 1 lM  zVAD-fmk at 20 lM for 1 h and then treated with hTNF (600 IUmL1). (A) Effect of
Sibiriline on RIPK1-dependent necroptosis induced by TNF+TAK1i+zVAD in immortalized MEFs (% cell death, n = 3, mean  SD, *P < 0.05;
caspase-3 activity AU, n = 3, mean  SD, *P < 0.05). Results shown are representative of at least three independent experiments. (B) Effect
of Sibiriline on RIPK1-dependent apoptosis induced by TNF+TAK1i in immortalized MEFs. (% cell death, n = 3, mean  SD, *P < 0.05;
caspase-3 activity AU, n = 3, mean  SD, *P < 0.05). Results shown are representative of at least three independent experiments.
Fig. 6. Effect of Sibiriline on the catalytic activity of RIPK1. (A) RIPK1 was treated with 5, 10, or 50 lM of the mentioned chemical
compound to analyze the effect on the kinase autophosphorylation. Radioactive autophosphorylation assays were processed with ATP-c32P
at 30 lM final concentration. Necrostatin-1, a well-described inhibitor of RIPK1, was used as an internal control. Coomassie staining was
performed in order to estimate the total amount of protein loaded on polyacrylamide gel. Autophosphorylated RIPK1 band was visualized on
radiographic film. Assays were performed at least two times, and similar results were obtained each time. The representative images are
shown: (B) Sibiriline inhibits the catalytic activity of RIPK1. GST-RIPK1 full length produced by baculovirus in Sf9 insect cells was assayed in
the presence of increasing concentrations of Sibiriline with myelin basic protein, MBP, as a substrate. Kinase activities are expressed in %
of maximal activity, i.e., measured in the absence of inhibitor. The value marked with a circle corresponds to 10 lM Nec-1s (n = 3,
mean  SD). (C) High concentration of ATP has an effect on the inhibition of RIPK1 autophosphorylation by Sibiriline. The cold ATP (0.25 or
1 mM) was used to study the competition with Sibiriline. These assays are similar to those described in (A). Necrostatin-1, a known ATP-
competitive inhibitor of RIPK1, was used as an internal control. % of RIPK1 activity inhibition is calculated through a ratio with DMSO (-), as
a 0 percent reference. The normalization between samples was performed using the quantification of proteins. (D) No effect of Sibiriline on
the catalytic activity of RIPK3. GST-RIPK3 full length produced by baculovirus in Sf9 insect cells was assayed in the presence of increasing
concentrations of Sibiriline with myelin basic protein, MBP, as a substrate. Kinase activities are expressed in % of maximal activity, i.e.,
measured in the absence of inhibitor. The value marked with a circle corresponds to 10 lM of GSK’872, a reference RIPK3 inhibitor (n = 3,
mean  SD).
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USA). HT29 cells were cultured in EMEM (Eurobio, Les
Ulis, France) supplemented with 10% FCS and 2 mM L-
glutamine. Jurkat, FADD-deficient Jurkat and U937 cells
were cultured in RPMI containing Glutamax (Invitrogen/
Thermo Fisher Scientific) supplemented with 15% FCS.
RPE-1 hTERT cells were cultured in DMEM-F12 contain-
ing Glutamax (Invitrogen/Thermo Fisher Scientific) supple-
mented with 10% FCS. All cells were cultured under a 5%
CO2 atmosphere at 37 °C.
Chemicals and biological compounds
Recombinant human Flag-tagged TRAIL (TRAIL-Flag) and
zVAD-fmk were obtained from Enzo Life Sciences (Villeur-
banne, France). Necrostatin-1 (Nec-1) and necrostatin-1s
(Nec-1s) were from Calbiochem (VWR International, Fonte-
nay-sous-Bois, France). The TAK1 kinase inhibitor, NP-
009245, was from AnalytiCon Discovery GmbH (Postdam,
Germany). Anti-Flag M2 IgG1 antibody, cycloheximide
(CHX), and PI were obtained from Sigma-Aldrich (St Quen-
tin-Fallavier, France). TNFa were obtained from Invitrogen/
Thermo Fisher Scientific. This TNF was used in the screen of
new necroptosis inhibitors. Recombinant human TNFa was
also produced and purified to at least 99% homogeneity at
VIB Protein service facility (Ghent, Belgium). It has a specific
biological activity of 6.8 9 107 IUmg1 and was used at
2000 IUmL1 (67 ngmL1) in FADD-deficient Jurkat or at
600 IUmL1 (20 ngmL1) in MEFs. The multiaggregated
Ig-CD95L (or Ig-FasL) was a kind gift of Dr P. Legembre
(CLCC Eugene Marquis, Rennes, FR) and was used at
200 ngmL1.
Synthesis of 4-(1H-pyrrolo[2,3-b]pyridin-2-yl)phenol
(Sib): following literature procedure [46], a solution of
3-picoline (200 mg, 2.2 mmol, 1 eq) in anhydrous THF
(10 mL) was added dropwise to a solution of LDA (freshly
prepared by adding nBuLi (1.5 mL, 2.5 M solution in hex-
anes, 3.9 mmol) to diisopropylamine (0.54 mL, 3.9 mmol)
in anhydrous THF (10 mL)) at 0 °C under argon atmo-
sphere. The orange mixture was stirred for 20 min before
dropwise addition of a solution of 4-methoxybenzonitrile
(316 mg, 2.2 mmol, 1 eq) in anhydrous THF (10 mL).
After 1 h at 0 °C, more LDA solution in THF (10 mL,
3.9 mmol, prepared as above) was added dropwise and the
reaction was slowly warmed to RT over 1 h before being
heated to reflux in a water bath for 2 h. After cooling, the
yellow solution was quenched carefully with saturated
A
B
C
Fig. 8. Sibiriline interacts closed to the
RIPK1 ATP-binding pocket. (A) Close-up
view of the interaction between Sib and
surrounding residues in RIPK1 reporting the
contact residues determined after MD
optimization of the best position of Sib
obtained upon docking: (a) Bold residues
are the seven key amino acids involved in
the interaction with necrostatins (as
reported in Xie et al.) [40]; (b) italic residues
are defining the pharmacophore derived
from LigandScout analysis. (B) View of the
overall structure of Sib-bound RIPK1
highlighting the bridging contact performed
by Sib between both protein subdomains.
Activation loop defined by residues Asp156
to Glu196 is shown in red. (C)
Superimposition of the model to the X-ray
structure 4ITH obtained for the complex
formed by Nec-1s (orange sticks) with
RIPK1.
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NH4Cl (10 mL) and water (40 mL) was added. The precip-
itate was filtered, washed with diethyl ether and water,
dried under vacuum to afford 2-(4-methoxyphenyl)-1H-pyr-
rolo[2,3-b]pyridine as a light yellow solid (327 mg, 68%).
Analytical data are in accordance with the literature.
2-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridine (100 mg,
0.44 mmol) was suspended in anhydrous dichloromethane
(5 mL) and cooled to 78 °C. Boron tribromide (1.3 mL
of 1 M solution on dichloromethane, 1.3 mmol, 3 eq) was
added dropwise and the dark red mixture was stirred for
16 h while warming to RT. The reaction was carefully
quenched with water, dichloromethane (10 mL) was added,
and the solid was dissolved by addition of 1 M sodium
hydroxide (15 mL). After stirring for 10 min, the aqueous
phase was washed with dichloromethane (2 9 10 mL) and
the pH was adjusted to 5 with 1 M hydrochloric acid. The
resulting precipitate was filtered, washed with water, and
dried under vacuum to obtain a tan solid (68 mg, 74%).
1H NMR (300 MHz, DMSO-d6): 11.93 (bs, 1H), 9.71 (bs,
1H), 8.14 (dd, J = 4.7, 1.3 Hz, 1H), 7.85 (dd, J = 7.8,
1.3 Hz, 1H), 7.76 (d, J = 8.7 Hz, 2H), 7.02 (dd, J = 7.8,
4.7 Hz, 1H), 6.85 (d, J = 8.7 Hz, 2H), 6.70 (d, J = 2.0 Hz,
1H). 13C NMR (75 MHz, DSMO-d6): 157.7, 149.6, 141.9,
139.0, 127.1, 126.9, 122.7, 121.3, 115.9, 115.8, 95.1. MS
(ESI): m/z 211 [M+H]+. Synthesis of the inactive derivative
Sib-i has been described previously [47].
Cell-based screening assay for characterization of
necroptosis inhibitors
The details of the cell-based assay used to screen a library of
small chemical compounds have been described in Miao and
Degterev [39]. The Jurkat FADD-deficient I 2.1 cell line was
maintained in RPMI 1640 medium (Gibco/Thermo Fisher
Scientific, Carlsbad, CA, USA) containing Glutamax and
15% fetal calf serum (Eurobio). Necroptosis was induced by
addition of 10 ngmL1 of human recombinant TNF-a (Invi-
trogen/Thermo Fisher Scientific). Necrostatin-1 (Nec-1; Cal-
biochem) was used as model necroptosis inhibitor. Cells were
maintained in 75 cm2 flask and passaged every 2 or 3 days.
Chemical collections analyzed were formatted in 96-well
plates with 80 molecules per plate at 10 mM in 100% DMSO.
For each collection plate, two cell plates were seeded (one
treated with TNF-a and the other one without TNF-a). Cells
were seeded at 20 000 cells per well, in 40 lL of medium, in a
96-well clear, flat bottom plate (CytoOne, Starlab) before
treatment. Then, 40 lL of medium with or without TNF-a
at 25 ngmL1 was added to all wells in the corresponding
plate. Immediately after TNF-a addition, 20 lL of diluted
compound at 50 lM was added to the plates. Final concen-
tration of each chemical compound was 10 lM at 0.1%
DMSO. Eight positive (Nec-1 at 10 lM final) and eight nega-
tive (DMSO) controls were used in each plate to validate the
assay. Cells were incubated at 37 °C, 5% CO2 for 24 h
before performing MTS viability assay, described hereafter.
Compounds were diluted before treating cells. Liquid han-
dling was performed using the Nimbus Microlab liquid han-
dler (Hamilton Robotics, Bonaduz, Switzerland) under
microbiological safety workbench. The stock solutions of
compounds at 10 mM were diluted directly in culture medium
to obtain a solution at 50 lM before treating cells.
Cell death assays
Cell viability was measured by a water soluble tetrazolium
compound MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxy-
methoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt)
(CellTiter 96 AQueous Non-Radioactive Cell Proliferation
Sib
Nec-1s
Sib-i
Fig. 9. Contact residues (3.5 A cut-off distance) predicted for the interaction of active and inactive inhibitors with human RIPK1, in
comparison with those of the experimental Nec-1s-RIPK1 structure. Comparison between active compounds (Sib, top row and Nec-1s,
bottom row) and the inactive compound (Sib-i, middle row) indicates that the inactive compound shares many of the interactions with one
or both active inhibitors, with the notable exception of the contacts with the residues between 129 and 136, which are present in both
active inhibitors. The position of a good inhibitor should therefore promote hydrophobic interactions with the end of the long C-domain helix
defined by residues 111Pro to 132Lys, thereby reducing the mobility of the two main subdomains of the kinase toward each other.
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Fig. 10. Sibiriline prevents concanavalin A-induced hepatitis in vivo. C57Bl/6 WT mice were pretreated for 1 h with intraperitoneal
administration of 3 mgkg1 Sib or 6.25 mgkg1 Nec-1s diluted in vehicle before intravenous administration of 12 mgkg1 concanavalin A.
At the end of treatment, mice were sacrificed (vehicle, n = 5; Sib, n = 4; Nec-1s, n = 4; vehicle + concanavalin A, n = 10;
Sib + concanavalin A, n = 13; Nec-1s + concanavalin A, n = 10). (A) Serum levels of AST and ALT were determined at 24 h post-
concanavalin A injection as described in Materials and methods. Mean  SEM *P < 0.05 and **P < 0.01. (B) Hematoxylin and eosin-stained
liver sections were shown. Scale bars represent 500 lm. (one picture representative for each group of mice). (C) Percentage of liver
necrosis was determined 24 h after concanavalin A treatment in each group (vehicle + concanavalin A, n = 6; Sib + concanavalin A, n = 6;
Sib-i + concanavalin A, n = 6) as described in Materials and methods. Mean  SEM *P < 0.05 and **P < 0.01.
14 The FEBS Journal (2017) ª 2017 Federation of European Biochemical Societies
Sibiriline, a RIPK1 inhibitor preventing hepatitis F. Le Cann et al.
Assay; Promega, Fitchburg, WI, USA), according to the
manufacturer’s instructions. This method is based on the
reduction of MTS tetrazolium compound by viable cells to
generate a colored formazan product. Human peripheral
blood leukocytes (PBL) and human RPE-1 hTERT cells
were seeded in 96-well plates at 2.5 9 105 or 8 9 103 cells
per well, respectively. After 24 h of treatment, 20 lL of assay
solution was added. After 3-h incubation at 37 °C, the absor-
bance at 490 and 630 nm was measured by a microplate
reader (SPECTROstar Nano, BMG Labtech). The results
were corrected by subtracting the background reading (after
2-h incubation with blank medium) and viability was calcu-
lated with % viability = mean (OD490  OD630) sample/
mean (OD490  OD630) control 9 100.
Detection of necrotic cells was done by using PI staining
(500 ngmL1) and flow cytometry analysis. U937, Jurkat,
or L929 sAhFas cell lines were seeded at 2.5 9 105 cells
per well in 24-well plates. Concerning necroptotic models,
U937 cells were pretreated with zVAD-fmk (30 lM) for
30 min and then treated for 20 h with TRAIL-Flag
(200 ngmL1) and 2 lgmL1 M2 anti-Flag antibody.
L929 sAhFas cells were pretreated with zVAD-fmk (20 lM)
for 30 min and then with TNF (10 ngmL1) or Ig-FasL
(200 ngmL1) for 16 h. FADD-deficient Jurkat cells were
treated with 10 ngmL1 TNF. As for apoptotic models,
wild-type Jurkat cells were treated either with TRAIL-Flag
(20 ngmL1) and 2 lgmL1 M2 anti-Flag antibody, Ig-
FasL (200 ngmL1), or staurosporine (100 nM) for 18 h.
After treatment, percentage of PI-positive cells was deter-
mined by flow cytometry analysis of fluorescence (FL-2)
(FACScalibur, Becton Dickinson, Le Pont de Claix,
France) and expressed as %/NT.
Clonogenic assay
After treatment with TNF/zVAD-fmk in the presence or
absence of inhibitory compounds (Sib, Sib-i, Nec-1, or
Nec-1s) as described above, L929 cells were seeded out in
an appropriate dilution, here 1000 cells per well (in six-well
plates), and allow for 8 days to form colonies. The subse-
quent colonies were fixed with ice cold methanol and
stained with crystal violet (50% ethanol).
RIPK1 and RIPK3 kinase assays
Human RIPK1 full-length GST-tagged was expressed by
baculovirus in Sf9 insect cells (product #R07-10G; Sig-
nalChem, Richmond, CA, USA). The protocol used to
detect the enzymatic activity is adapted from Degterev
et al. [6]. For detection of RIPK1 autophosphorylation,
kinase reaction was initiated mixing 5 lL of RIPK1, 5 lL
of 3 9 kinase reaction buffer (5 mM MOPS pH 7.2,
2.5 mM glycerol 2-phosphate, 4 mM MgCl2, 2.5 mM MnCl2,
1 mM EGTA, 0.4 mM EDTA, 50 lgmL1 BSA, or
0.05 mM DTT), 2 lL H2O, and 3 lL of the tested mole-
cule. The mixture was kept on ice for 10 min. During the
incubation, the ATP solution was prepared by mixing 5 lL
of 3 9 kinase reaction buffer, 4 lL H2O, 6 lL cold ATP
at 150 lM, and 2 lCi of [c-32P] ATP. This ATP solution
was then mixed with RIPK1 and the tested compound, and
was incubated for 30 min at 30 °C. Reactions were stopped
by boiling in 5 lL of loading buffer for 3 min at 95 °C.
Twenty-five microliter of each reaction were loaded per
well in precast NuPage 12% Bis-Tris gel (Thermo Fisher
Scientific) and analyzed by SDS/PAGE. Autophosphory-
lated RIPK1 band was visualized by analysis in a Typhoon
Phosphorimager (GE Healthcare Life Sciences, Velizy-Vil-
lacoublay, France). Alternatively, the kinase activity of
RIPK1 can be detected using the ‘gold standard’ P81 phos-
phocellulose assay. Note here that the P81 ion exchange
chromatography paper (GE Healthcare) used in this study
is no longer provided by the manufacturer. For a final vol-
ume of 30 lL, 2 lL of kinase was assayed in buffer
described above with 0.1 lglL1 of MBP (#M1891;
Sigma) as substrate and in the presence of 15 lM [c-33P]
ATP (3000 Cimmol 1; 10 mCimL 1). Controls (maximal
kinase activity) were performed with appropriate dilutions
of dimethylsulfoxide. After extensive washes with a solution
of phosphoric acid at 1% in water using a FilterMate Har-
vester (PerkinElmer, Waltham, MA, USA), the wet filters
were counted in the presence of 20 lL ACS (GE Health-
care) scintillation fluid using a TopCount Scintillation and
Luminescence Counter (PerkinElmer).
The kinase activity of RIPK3 (human, recombinant,
expressed by baculovirus in Sf9 insect cells) was detected in
RIPK1 buffer with 0.1 lglL1 of MBP as substrate follow-
ing the P81 phosphocellulose assay described here before.
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Fig. 11. Sibiriline reduces the loss of mouse body weight induced
by concanavalin A treatment. C57Bl/6 WT mouse body weights
were determined 24 h post-treatment in each group (vehicle,
n = 5; Sib, n = 4; Nec-1s, n = 4; vehicle + concanavalin A, n = 10;
Sib + concanavalin A, n = 13; Nec-1s + concanavalin A, n = 10).
Mean  SEM *P < 0.05.
15The FEBS Journal (2017) ª 2017 Federation of European Biochemical Societies
F. Le Cann et al. Sibiriline, a RIPK1 inhibitor preventing hepatitis
Kinase binding assays
Binding assays were performed by DiscoverX (Fremont).
These assays are based on a competition binding assay that
quantitatively measures the ability of a compound to com-
pete with an immobilized, active site-directed ligand. See
Fabian et al. for details on this assay technology [48]. In
brief, streptavidin-coated magnetic beads were mixed with
biotinylated small-molecule ligands to generate affinity resins
for the assay. After blocking, binding reactions were assem-
bled by combining DNA-tagged kinases, inhibitors, and
liganded affinity beads. The ability of the tested compound
to compete with the immobilized ligand is measured via
quantitative PCR of the DNA tag. The percent inhibition
was calculated by measuring the amount of kinase captured
on the solid support as a function of the test compound con-
centration. In this study, binding assays were used for (a) the
analysis of selectivity against a large panel of kinases (service
‘KINOMEscan’) and for (b) the determination of binding
constant (Kd) of small chemical compound for RIPK1 (ser-
vice ‘KdELECT’). Dissociation constants (Kds) are calcu-
lated by measuring the amount of kinase captured on the
solid support as a function of the test compound concentra-
tion with top concentration being 30 000 nM.
Analysis of cell death and caspase-3 activation
Mouse embryonic fibroblasts were seeded at 7500 cells per
well in 96-well plates. The next day, cells were pretreated
with the indicated compounds for 30 min and then stimu-
lated with human TNF (600 IUmL1) in combination with
1 lM TAK1i with or without 20 lM zVAD-fmk in the pres-
ence of 5 lM SytoxGreen (Invitrogen/Thermo Fisher Scien-
tific) and 20 lM DEVD-MCA (PeptaNova GmbH,
Sandhausen, Germany). SytoxGreen intensity and caspase-
3 activation were measured at intervals of 1 h using a Flu-
ostar Omega fluorescence plate reader (BMG Labtech
GmbH, Ortenberg, Germany), with excitation/emission fil-
ters of 485/520 nm for SytoxGreen and 360/460 nm for
DEVD-MCA, gains set at 1100, 20 flashes per well, and
orbital averaging with a diameter of 3 mm. Percentage of
cell death was calculated as (induced fluorescence  back-
ground fluorescence)/(maximal fluorescence  background
fluorescence) 9 100. The maximal fluorescence is obtained
by full permeabilization of the cells using Triton X-100 at a
final concentration of 0.1%. The caspase-3 activity was cal-
culated as (induced DEVD-AMC fluorescence  back-
ground fluorescence) 9 100/(SytoxGreen fluorescence
obtained from the Triton X-100 permeabilized cells).
ATP concentration measurement
U937 and L929 sAhFas were seeded at 2 9 104 cells per
well in white 96-well plates for 24 h. U937 cells were pre-
treated with zVAD-fmk (30 lM) for 30 min and then
treated for 20 h with TRAIL-Flag (200 ngmL1) and
2 lgmL1 M2 anti-Flag antibody. L929 sAhFas cell line
were pretreated with zVAD-fmk (20 lM) for 30 min and
then treated with mouse TNF (10 ngmL1) or Ig-FasL
(200 ngmL1) for 16 h. Concentration of cellular ATP was
measured using CellTiter-Glo Luminescent Cell viability
assay (Promega) according to the manufacturer’s instruc-
tion and as previously described [22]. ATP concentration
was expressed as %/NT  SD.
Molecular docking
In order to complete the RIPK1 structure available from
PDB structures, we performed homology modeling of full
RIPK1 protein, notably for the completion of the missing
residues. The selected template was ITHJ_B as only loop
177REVDGTAKKNGG188 was missing in this structure.
Homology modeling did not seem reliable because it did
not propose any structuration of this loop despite PSSPred
results predicting that a majority of residues should be
involved in alpha-helix secondary structure. PEPFold ab-
initio method allowed us to model the loop efficiently and
finally enabled us to complete the RIPK1 model for molec-
ular docking computations. Next, a normal mode analysis
(NMA) was achieved with ElNemo program to modulate
the RIPK1 conformations available from the initial model,
improving the variety of protein structures that will be used
during docking by the addition of two more models for
RIPK1 after modes selection (following ElNemo standard
validation of essential modes). The final three models of
RIPK1 were used as biological target (receptor) for the
exploration of possible association modes with compounds
Nec-1s, Sib, and Sib-i. Docking calculations were per-
formed by using the standard protocol proposed in the
VINA implementation of YASARA suite (global docking,
1000 runs per target/per compound). Results have been
clusterized, thanks to the g cluster command of the Gro-
macs program (Jarvis–Patrick method). After ranking of
the poses, the best positioning of the ligand toward the
receptor (energy criteria) was submitted to a short molecu-
lar dynamics simulation in water for 10 ns in order to
improve the model of compound-RIPK1 complex. Final
models were obtained after energy minimization after
checking that the ligand was stable during the MD trajec-
tory. Ligand-contacting residues were detected using a
3.5 A cut-off distance and pharmacophores were derived
from a standard analysis by using Ligand Scout program.
Concanavalin A-induced hepatitis
Seven- to nine-week-old female C57Bl/6 WT mice were pur-
chased from Janvier (Le Genest St Isle, France). Con-
canavalin A was provided by Sigma-Aldrich and diluted at
12 mgkg1 in PBS/5% DMSO (vehicle). C57Bl/6 WT mice
were pretreated for 1 h with intraperitoneal administration
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of 3 mgkg1 Sib or 6.25 mgkg1 Nec-1s diluted in vehicle
before retro-orbital administration of 12 mgkg1 con-
canavalin A for 24 h. At the end of treatment, mice were
sacrificed (vehicle, n = 5; Sib, n = 4; Nec-1s, n = 4; vehi-
cle + concanavalin A, n = 10; Sib + concanavalin A,
n = 13; Nec-1s + concanavalin A, n = 10). All animals
received human care and all study protocols comply with
the institution’s guidelines. Authors were authorized to lead
animal experimentation by ‘La direction des Services Veteri-
naires’ (license M Samson #A3523840), and the project was
authorized by the Comite Regional d’Ethique d’Experimen-
tation Animal CREAA (license given by the ‘Ministere de
l’Education Nationale et de la Recherche’ # 7576).
At the end of the experiment, mice body weights were
measured and fragments of mouse livers were fixed in 4%
paraformaldehyde and embedded in paraffin for hema-
toxylin/eosin staining. Serum AST and ALT were measured
in mouse serum according to the IFCC primary reference
procedures and using the Olympus AU2700 Autoanalyser
(Olympus France, Rungis, France). The percentage of liver
necrosis was determined using image analysis software
(NDP view, Hamamatsu). The total liver area taken into
account was comprised between 18 and 51 mm2.
Statistical analyses
Data presented were acquired from a minimum of three
independent experiments. They are expressed as means 
SD or  SEM. Statistical analyses for in vitro studies were
performed with unpaired t tests. For in vivo studies, Mann–
Whitney U test was used for comparison of control group
parameters with treatment group. All statistical analyses
were performed with GRAPHPAD PRISM6 software (GraphPad
Software, San Diego, CA, USA).
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